Last reviewed · How we verify
NCT04907916
Sirtuin1 in COVID19 Patients
trial testing SIRTUIN1 in Covid19 in 130 participants. Status unknown.
1 August 2022
Quick facts
| Lead sponsor | Assiut University |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 130 |
| Start date | 1 June 2021 |
| Primary completion | 1 August 2022 |
| Estimated completion | 1 January 2023 |
Drugs / interventions tested
- SIRTUIN1
Conditions studied
- Covid19 — all drugs for Covid19 →
Sponsor
Assiut University
Who can join
Adults 18 to 65, any sex, with Covid19. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
1. Evaluate serum level of NAD,Sirtuin1,ADAM17 andPARP1 in covid19 patients 2. Investigate the correlation between measured biomarkers and each other 3. Investigate the correlation between measured biomarkers and each other and their correlation with covid19 severity and outcome which may help in the therapy and prevention of disease complication(cytokine storm)
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Crosstalk between hypoxic cellular micro-environment and the immune system: a potential therapeutic target for infectious diseases.
Akinsulie OC, Shahzad S, Ogunleye SC, Oladapo IP, et al · · 2023 · cited 11× · PMID 37600803 · DOI 10.3389/fimmu.2023.1224102
Verify or expand the search:
- PubMed search for NCT04907916
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Covid19
Currently open trials in the same condition.
- NCT03305341 — Proof-of-Concept Clinical Pharmacology Trial for COVID-19 Antigen Presentation Therapeutic Biologic Mix · EARLY_PHASE1 · active not recruiting
- NCT06482138 — Dysfunction of Olfaction After COVID-19 Infection: Morphological and Histomolecular Investigation · NA · recruiting
- NCT04924803 — Community Developed Technology-Based Messaging to Increase COVID-19 Vaccine Uptake Among People Who Inject Drugs · NA · active not recruiting
- NCT05013632 — COVID-19 International Drug Pregnancy Registry · recruiting
- NCT04806061 — Urine Alkalinisation in COVID-19 · NA · active not recruiting
Other Assiut University trials
Trials by the same sponsor.
- NCT07423312 — Lead Exposure and Multiple Sclerosis · not yet recruiting
- NCT07234526 — Usage of Glucose Fluctuations as a Prognostic Marker in Septic Shock Patients · not yet recruiting
- NCT07273214 — Knowledge, Attitude and Practice of Third Trimester Pregnant Mothers Towards Self-Medication in Assiut, Egypt · not yet recruiting
- NCT07194863 — Efficacy of Essential Phospholipid Versus Betaine HCL/L-Glutamic Acid in MAFLD · not yet recruiting
- NCT07053709 — Screening for Hyperuricemia in Patients With Metabolic Associated Fatty Liver Disease (MAFLD) · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04907916 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Assiut University
- Last refreshed: 1 June 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04907916.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing